Eisai announces launch of Pariet triple formulation combination packs in Japan

The launch will feature three products: Rabecure Pack 400 and Rabecure Pack 800, which package together individual blister sheets each containing a daily triple formulation dose of Pariet, amoxicillin hydrate and clarithromycin for use in primary H. pylori eradication, and Rabefine pack, which similarly packages together individual blister sheets containing a daily triple formulation dose of Pariet, amoxicillin hydrate and metronidazole for use in secondary H. pylori eradication.

Eisai received approval to manufacture and market both combination types in Japan from the country’s Ministry of Health, Labour and Welfare in August 2013, with all three products added to Japan’s National Health Insurance drug price list on 13 December of the same year.

In H. pylori eradication triple therapy with Pariet and two antimicrobial agents, successful eradication significantly depends on whether the patient properly adheres to the prescribed treatment regimen. Taking the incorrect dose or missing doses altogether can lead not only to reduced eradication rates but also to bacterial resistance.

With daily-dose blister sheets adopted for both the primary and secondary eradication combinations of Eisai’s new triple formulation packs, the launch is expected to help ensure that H. pylori eradication therapy is administered more appropriately and with greater certainty, while also improving patient drug compliance and offering increased convenience in a medical setting.

Eisai believes that the launch of its Rabecure and Rabefine combination packs will further promote the appropriate use of therapeutic agents in H. pylori eradication therapy and contribute to a wider range of treatment options available for gastric cancer eradication and other treatments for diseases associated with H. pylori.